Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Zhejiang Cancer Hospital

Reviewed by TrialFinderData Editorial Team · Updated

3 clinical trials · 3 recruiting · OTHER

Zhejiang Cancer Hospital has 3 clinical trials registered on ClinicalTrials.gov, with 3 actively recruiting participants. The trials listed below cover 8 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Zhejiang Cancer Hospital\'s Trial Portfolio

Zhejiang Cancer Hospital is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

3 of Zhejiang Cancer Hospital's 3 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Zhejiang Cancer Hospital's research footprint spans Gastric Cancer (2 trials), Hepatocellular Carcinoma (1), and Lenvatinib (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

is the largest single phase in Zhejiang Cancer Hospital's portfolio at 67% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Zhejiang Cancer Hospital

RECRUITINGPhase 2NCT05920863

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA...

This is a monocenter, single-arm, open-label study to evaluate the efficacy and safety of Lenvatinib combined with Tislelizumab and TACE applied as neoadjuvant regimen for the...

Sponsor: Zhejiang Cancer HospitalEnrolling: 351 location
Hepatocellular CarcinomaLenvatinibTislelizumab+3
RECRUITINGNCT07067983

Clinical Evaluation of GRAPE Model for Gastric Cancer Screening

A Prospective Study Evaluating the Performance of the GRAPE Model in Gastric Cancer Screening and Its Detection Rates Across Different Disease Stages

Sponsor: Zhejiang Cancer HospitalEnrolling: 10000001 location
Gastric Cancer
RECRUITINGNCT05991947

Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

This project aims to collect peripheral blood samples from newly diagnosed gastric cancer patients and healthy individuals. Various techniques such as cfDNA sequencing,...

Sponsor: Zhejiang Cancer HospitalEnrolling: 11001 location
Gastric CancerHealthy

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Zhejiang Cancer Hospital have on ClinicalTrials.gov?

Zhejiang Cancer Hospital has 3 clinical trials registered on the federal ClinicalTrials.gov registry, of which 3 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Zhejiang Cancer Hospital study?

Zhejiang Cancer Hospital's registered trials cover 8 conditions on ClinicalTrials.gov, led by Gastric Cancer (2 trials), Hepatocellular Carcinoma (1 trial), Lenvatinib (1 trial), Tislelizumab (1 trial), Tace (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Zhejiang Cancer Hospital clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 3 trials tracked for Zhejiang Cancer Hospital.